TASK DEFINITION: Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
PROBLEM: Paragraph: The company earned $728 million, or 67 cents per share, in the fourth quarter. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring. “Company sales were stronger than thought, but a lot of that upside came from drugs that are already off patent or about to lose patent protection,” said Edward Jones analyst Judson Clark. Excluding special items, Lilly earned 74 cents per share, matching analysts’ average forecasts, according to Thomson Reuters I/B/E/S. Shares in the company dropped 1.4 percent to 53.21, after earlier reaching their lowest in two weeks at $53.05. Lilly’s global sales fell 2 percent to $5.81 billion, but topped Wall Street forecasts of $5.46 billion. Sales would have been flat if not for the stronger dollar, which lowers the value of sales in overseas markets. Sales of Cymbalta, which lost U.S. patent protection last month, fell 38 percent to $883 million. But they came in about $100 million higher than Wall Street expected, analysts said. Lilly’s sales, earnings, and its share price, have been badly hurt since late 2011, when its Zyprexa schizophrenia drug lost U.S. patent protection. Once Lilly’s biggest product, with annual sales of $5 billion, it now has sales of only $1.5 billion. The situation worsened last month, when Cymbalta - which also had $5 billion in annual sales at its peak - began facing cheaper generics in the United States. The company’s “patent cliff” will become more daunting in March, when $1 billion-a-year osteoporosis drug Evista faces U.S. generics. “We haven’t wasted the crisis,” Chief Executive John Lechleiter said Thursday in a conference call with industry analysts. “We’re more agile, we’re leaner and I believe we’re better operators today.”  Lilly has cut more than 5,000 employees from its workforce in order to reduce annual costs by $1 billion over the last three years to deal with patent expirations on its drugs. It has also restructured itself to focus on cancer and diabetes - lucrative specialties that are two of the company’s longstanding strengths. Clark said sales of Cymbalta could eventually decline 80 percent, which has been the case for many other blockbuster medicines in recent years. He questioned whether gains for other products seen in the fourth quarter will be sustainable. Sales of many products over the quarter showed double-digit sales increases, including Lilly’s Humalog insulin, Cialis anti-impotence treatment, Forteo and Evista osteoporosis drugs, and Straterra for attention deficit disorder. But price increases in the United States accounted for much of those sales gains. The Indianapolis drugmaker is expecting a return to company sales growth next year, from increased sales of drugs that still have patent protection and from launches of new treatments for cancer and diabetes. It hopes to launch three new drugs this year: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of the disease, which is closely linked to obesity. Although analysts have forecast annual sales of more than $650 million for ramucirumab, they are concerned the new diabetes drugs may have a hard time competing with similar drugs already on the market. The company has introduced no new products in recent years. In a recent interview, Lechleiter said it was time for Lilly “to go back on offense”, helped by a pipeline of nearly 40 medicines in mid- and late-stage studies, compared with only seven in those stages of development a decade ago. Claim: Lilly's quarterly sales largely offset Cymbalta slide.

SOLUTION: Drugmaker Eli Lilly and Co’s quarterly revenue fell far less than expected, it reported on Thursday, as plunging sales of its Cymbalta depression treatment were largely offset by higher revenues for most of its other prescription drugs.

PROBLEM: Paragraph: A 34-year-old woman from Loudi city in the central province of Hunan confessed to poisoning the yoghurt drink before delivering to the students, Xinhua said on Saturday. It said the woman was suspected to be suffering from a mental disorder. Three children were in serious condition but their lives were not in danger, Xinhua said. Investigations were going on. There have been several attacks on schools in China in recent years while at the same time, food safety has become a contentious issue with a rising number of food-poisoning cases due in part to lax safety standards at small factories. Claim: Nineteen students sick in China from poisoned yoghurt.

SOLUTION: Nineteen primary school children in China have been hospitalized after drinking yoghurt said to be laced with rat poison and herbicide, the Xinhua state news said.

PROBLEM: Paragraph: The purpose of the fund is to assist developing countries with weak health systems in addressing the crisis as well as to tackle the long-term consequences. The United Nations could make a formal announcement this week, the ministry said. Norway, which suggested the fund, has not committed how much money it would put into the initiative, similar to a 2014 United Nations Ebola Response Fund. “We want to make sure that the efforts are as unified as possible and as early as possible so that we can answer up to the demands that countries will have, especially the poorest countries,” Foreign Minister Ine Eriksen Soereide told Reuters. Almost 340,000 people have been infected by the novel coronavirus across the world and more than 14,500 have died, with deaths in Italy surpassing the toll in China, where the outbreak began, according to a Reuters tally. In Africa, Angola, Eritrea and Uganda have confirmed their first cases, while Mauritius recorded its first death as the virus spreads across the continent despite efforts by governments to hold it back. In the Middle East, the first two cases of coronavirus were confirmed in the densely populated Gaza Strip on Sunday. U.N. Secretary-General Antonio Guterres on Thursday called on wealthy countries to not just think about their citizens but help less-prepared nations tackle the crisis. “A wealthy country must not be convinced that it has only to deal with its own citizens. It’s in the interests of a wealthy country to contribute to a global response because the crisis can come from wherever, at any moment,” he told reporters. Claim: U.N. to create global coronavirus fund, Norway says.

SOLUTION:
The United Nations will create a fund to prevent the spread of coronavirus and support the treatment of patients worldwide, Norway said on Monday.